Evidence map›Paper›PMID 41104603›Full record

ArticleAlzheimer's & dementia : the journal of the Alzheimer's Association2025

Examination of metabolic syndrome in Down syndrome and association with dementia.

Dina Dass, Lam-Ha T Dang, Laura Xicota, Sharon Krinsky-McHale, Balaji Kannappan, Adam M Brickman, Bradley T Christian, Elizabeth Head, Sid E O'Bryant, Mark Mapstone and 4 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Alzheimer's & dementia : the journal of the Alzheimer's Association, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Review
  3. Use of anti-amyloid-β monoclonal antibodies in persons with Down syndrome Alzheimer's disease.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026
    Review
  4. Examination of metabolic syndrome in Down syndrome and association with dementia.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Dina DassColumbia University Irving Medical Center, New York, New York, USA.ORCID 0009-0008-9252-0789
Lam-Ha T DangColumbia University Irving Medical Center, New York, New York, USA.
Laura XicotaColumbia University Irving Medical Center, New York, New York, USA.
Sharon Krinsky-McHaleDepartment of Psychology, NYS Institute for Basic Research in Developmental Disabilities, Staten Island, New York, USA.
Balaji KannappanColumbia University Irving Medical Center, New York, New York, USA.
Adam M BrickmanColumbia University Irving Medical Center, New York, New York, USA.
Bradley T ChristianUniversity of Wisconsin-Madison, Madison, Wisconsin, USA.
Elizabeth HeadDepartment of Pathology & Laboratory Medicine, University of California, Irvine, Irvine, California, USA.
Sid E O'BryantUniversity of North Texas, Health Science Center at Fort Worth, Fort Worth, Texas, USA.
Mark MapstoneUniversity of California, Irvine, Irvine, California, USA.
Benjamin HandenUniversity of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, USA.
Karen MarderColumbia University Irving Medical Center, New York, New York, USA.
Joseph H LeeColumbia University Irving Medical Center, New York, New York, USA.ORCID 0000-0002-2000-4821
Alzheimer Biomarker Consortium – Down syndrome (ABC‐DS)

Funding

Research Education CoreP30AG066462 · NIA · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI PHILIP L DE JAGER · 2020 to 2026
$30.1M
The Alzheimer's Disease Research Center at the University of California, IrvineP30AG066519 · NIA · UNIVERSITY OF CALIFORNIA-IRVINE · PI Mathew Mark Blurton-Jones · 2020 to 2026
$27.9M
Waisman Center Intellectual and Developmental Disabilities Research CenterP50HD105353 · NICHD · UNIVERSITY OF WISCONSIN-MADISON · PI Qiang Chang · 2021 to 2026
$8.5M
Cerebrovascular contributions to Alzheimer's disease in adults with Down SyndromeRF1AG079519 · NIA · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI BRICKMAN, ADAM M, HEAD, ELIZABETH · 2022 to 2022
$3.1M
Alzheimer's Disease Research CentersColumbia University Irving Medical CenterDevelopmental Disabilities Research CentersDisease and Related DementiasEunice Kennedy Shriver IntellectualFulbourn Hospital CambridgeHarvard Medical SchoolInstitute for Basic Research in Developmental DisabilitiesKentucky Neuroscience InstituteNational Institute of Child Health and Human DevelopmentNational Institute of Child Health and Human Development (NICHD)NCATS NIH HHSNIA NIH HHS P30 AG066462NIA NIH HHS P30 AG066519NIA NIH HHS RF1 AG079519NICHD NIH HHS P50 HD105353NIH HHSOffice for People With Developmental Disabilities N/ASanders-Brown Center on AgingUniversity of California, IrvineUniversity of Kansas Medical CenterUniversity of KentuckyUniversity of PittsburghUniversity of Wisconsin-MadisonWindsor Research Unit
6 · The paper itself

Abstract

introductionIn the neurotypical population, metabolic syndrome (MetS) is associated with Alzheimer's disease (AD). However, this has not been well studied in adults with Down syndrome (DS).

methodsThe prevalence of MetS and its subcomponents was examined in adults with DS using the Alzheimer Biomarkers Consortium - Down Syndrome data (ABC-DS, N = 389). Logistic regression was used to examine the relationship between MetS and AD at baseline visits.

resultsPrevalence of MetS, diabetes, hypertension, and hyperlipidemia was low with DS, even though the prevalence of obesity was elevated. Obesity was positively associated with AD in adults with DS (odds ratio = 2.79, P = 0.021), but there was no association between MetS and AD in DS. DISCUSSION: The prevalence of MetS was low in adults with DS. Although MetS was not associated with AD, obesity, a subcomponent of MetS, was associated with AD in adults with DS. This may inform targeted treatments in the future. HIGHLIGHTS: There was a low prevalence of metabolic syndrome (MetS) in adults with Down syndrome (DS). Overall MetS was not associated with dementia in adults with DS. Obesity, a subcomponent of MetS, had a high prevalence in adults with DS. Obesity was positively associated with dementia in adults with DS.

Indexed as

DementiaDown SyndromeMetabolic SyndromeAdultAgedFemaleHumansMaleMiddle AgedObesityPrevalenceAlzheimer's diseasedementiadiabetesDown syndromehyperlipidemiahypertensionmetabolic syndromeobesity

Identifiers

PMID41104603
PMCPMC12531894

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.